Volume 8 Supplement 1

Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis

Open Access

Collaborative models for increasing efficiency of early drug assessment

Journal of Pharmaceutical Policy and Practice20158(Suppl 1):O15

https://doi.org/10.1186/2052-3211-8-S1-O15

Published: 5 October 2015

Introduction

Several countries have set up early awareness and alert systems (EAAS) to inform their customers about technologies that may have a significant impact on the health care system [1].

Methods

The Austrian Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) implemented an EAAS specifically for oncologic drugs in 2009 [2]. Due to rising costs for cancer therapies, oncologic drugs are of importance throughout Europe and are therefore assessed concurrently by health technology assessment (HTA) agencies leading to considerable redundancies. Experiences of the LBI-HTA with applying different collaborative models used for the reduction of redundancies in the assessment of new oncologic drugs will be described.

Results

In order to identify potential ways of collaboration a workshop with 12 agencies from nine countries all involved in assessing new oncologic drugs was held in 2010. Following this workshop, the LBI-HTA started to send out "calls for collaboration" to identify partners interested in jointly conducting reports. Up until now, 11 calls have been sent out resulting in 15 collaborations with a total of six institutes. Collaboration initially led to some delays in report production, but since the same agencies repeatedly indicated interest in collaboration, familiarity with processes and development of trust was eventually achieved ultimately leading to efficiency gains.

Besides the active production of joint reports, rapid relative effectiveness assessments produced in international collaboration within the European HTA Network EUnetHTA can serve as basis for local reports [3]. So far, four assessments on pharmaceuticals have been published by EUnetHTA of which one addressed an oncologic drug. This assessment was enriched with local and context-specific information and therefore allowed a fast and less resource-intense production of a report.

Conslusions

Increasing financial pressure on health care systems and limited research resources necessitate exploring ways of sharing and reusing research findings. Local initiatives driven by individual agencies but also European-wide developments offer the opportunity to produce assessments more efficiently and to reduce redundancies.

Authors’ Affiliations

(1)
Ludwig Boltzmann Institute for Health Technology Assessment

References

  1. EuroScan International Network: A toolkit for the identification and assessment of new and emerging health technologies. 2014, EuroScan International Network: BirminghamGoogle Scholar
  2. Nachtnebel A, Geiger-Gritsch S, Hintringer K, Wild C: Scanning the horizon: development and implementation of an early awareness system for anticancer drugs in Austria. Health policy (Amsterdam, Netherlands). 2012, 104 (1): 1-11. 10.1016/j.healthpol.2011.11.003.View ArticleGoogle Scholar
  3. EUnetHTA: [cited 28.05.2015]; Available from: http://www.eunethta.eu/joint-assessments

Copyright

© Nachtnebel and Wild 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement